Lead Product(s) : Naltrexone Hydrochloride
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Hamden Group
Deal Size : Undisclosed
Deal Type : Agreement
Halberd Signs Development and Marketing Agreement for Medications & Nutraceuticals
Details : Under this agreement, Hamden will have worldwide exclusive rights to sell, market and distribute the HALB patented low-dose Naltrexone medication, and the HALB proprietary Vita-Shield-Max TM Nutraceutical Product.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 14, 2022
Lead Product(s) : Naltrexone Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Hamden Group
Deal Size : Undisclosed
Deal Type : Agreement